secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001437749-24-022484
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen expands PH80 global patent portfolio with new migraine treatment patents in four countries
--------------------------------------------------------------------------------

- New patents for PH80 migraine treatment issued/allowed in Australia, Hong Kong, Japan, and Mexico.
- All new patents expected to be in effect until 2040, subject to possible term extensions.
- PH80 is a non-systemic, hormone-free investigational pherine nasal spray for menopausal hot flashes and other conditions.
- Patents complement previously granted U.S. Patent No. 11,419,881 and EPO Patent No. 3955933 for migraine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924022484/0001437749-24-022484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924022484/vtgn20240710_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer